The rising prevalence of metabolic disorders, obesity, and type 2 diabetes has increased the global burden of liver diseases, creating a strong demand for advanced MASH treatment, effective fatty liver disease treatment, and innovative liver fibrosis treatment solutions. Metabolic dysfunction-associated steatohepatitis (MASH), previously known as non-alcoholic steatohepatitis (NASH), is a...